<DOC>
	<DOC>NCT01326546</DOC>
	<brief_summary>The purpose is to evaluate efficacy and safety of therapeutic hepatitis B virus (HBV) vaccine (synthesized peptide) Joint entecavir treatment in chronic hepatitis B patients.</brief_summary>
	<brief_title>Therapeutic Hepatitis B Vaccine (Synthesized Peptide εPA-44) Joint Entecavir in Treating Chronic Hepatitis B Patients</brief_title>
	<detailed_description>Eligible subjects are enrolled and assigned into 2 groups randomly with a 1:1 ratio： 1. Therapeutic HBV vaccine Joint Entecavir group：Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 + Oral intake entecavir 0.5mg per day ； 2. Empty liposome Joint Entecavir group：Inject empty liposome 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 + Oral intake entecavir 0.5mg per day. The study cycle consists of screening and enrollment period (week -4～0), treatment and follow-up period (week 0-96).</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>1. Aged 1865 years, male or female; 2. Conforming to diagnosis standard of chronic hepatitis B according to " 2005 Guideline for Prevention and Treatment of Hepatitis B " , (with positive HBsAg for more than 6 months), never have systemic treatment of antiHBV viral ,and HBVDNA ≥ 1.72×104 IU/ml； HBeAg (+), HBeAb ()； ALT within 2 to 10 times of ULN (upper limits of normal); 3. HLAA2 positive; 4. Compensatory liver disease having following hematological and biochemical parameters: WBC ≥ 3.5×109/L; ANC ≥ 1.5×109/L; PLT ≥ 80×109/L; Hb ≥ 100g/L; TBil ≤ 1.5 ULN; ALB not lower than low limit of normal value; BUN no more than high limit of normal value; Cr ≤ 1.5 ULN high limit of normal value; PT elongation ≤ 3 sec, APTT in normal value; Fasting blood glucose ≤ 7.0mmol/L; 5. TSH in normal value; 6. AFP test result no more than high limit of normal value; 7. Take effective contraception for subject with childbearing potential (including females and female partners of males); 8. Understand and sign ICF approved by EC; 9. Willing to comply with the study procedures and complete the study. 1. Antibodies of HCV, HDV or HIV is positive; 2. ANA titer ＞ 1:100; 3. Decompensated liver disease (such as gullet and pylorus varicose veins, hepatic encephalopathy); 4. Have the following illness or with severe disease inappropriate to participate in the study in the view of the investigator, in cardiovascular system: instable or significant cardiovascular illness such as angina pectoris, heart attack of myocardial infarction, congestive heart failure, severe hypertension, significant arrhythmia or abnormal ECG etc; Respiratory system: bronchiectasia, bronchial asthma, chronic obstructive pulmonary disease, respiratory failure, etc; Endocrine, metabolism diseases: diabetes mellitus, uncontrolled thyroid diseases, etc; Others: autoimmune disorder, active tuberculosis, malignancies (e.g.: tumor), neuropathic, metal, acute or chronic pancreatitis illness history, etc. 5. Have used antiHBV drug ( Interferon, Lamivudine, Adefovir Dipivoxil, Entecavir and Telbivudine ) and immunomodulator ( Thymic peptide, etc ) to the administration of study medication; 6. Have allergic diathesis or have suspected allergy to εPA44; 7. Female in pregnancy, lactation or those who plan to pregnancy during the course of the study; 8. Have history of alcohol abuse (Alcohol consumption for more than 5 years, with daily consumption over 40g for males and over 20g for females) and known drug dependence; 9. Have history of organ transplantation (except corneal transplantation and hair transplantation); 10. Have participated in any other drug clinical investigations within 3 months; 11. Any other factors inappropriate for enroll in the study or study completion in the view of the investigator.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Therapeutic HBV Vaccine</keyword>
	<keyword>Chronic Hepatitis B</keyword>
	<keyword>HBeAg positive</keyword>
</DOC>